Participant flow



Baseline characteristics table

	Treatment as usual (N=7)	Trial treatment (N=7)
Gender Male:Female	4:3	2:5
Age Mean (SD)	63.6 (19.3)	60.0 (17.6)
Affected hand Left: Right	3:4	4:3
Location of oedema Isolated digit: Global	2:5	3:4
Reason for oedema Trauma: Surgery	4:3	4:3
Days since injury Mean (range)	39.3 (21-59)	27.3 (3-45)
Past medical history	OA- not hand specific (n=2)	OA- not hand specific (n=3)
	Neuralgia	Type I DM
	Type II DM	Type II DM
	HTN (n=2)	HTN
	COPD	SOB
	Deaf	Under active thyroid
		Anxiety
Condition or operation:		
Distal radius fracture (conservative)	n=1 (14%)	n=2 (28%)
Dupuytren's release	n=1 (14%)	n=1 (14%)
Fracture/dislocation (digit)	n=2 (28%)	n=1 (14%)
Tendon repair and DR fracture	n=1 (14%)	n=0
Distal radius fracture fixation	n=1 (14%)	n=1 (14%)
Fracture/dislocation metacarpal	n=1 (14%)	n=0
Joint replacement	n=0	n=1 (14%)

Cumulative adherence rates.

Participant	Treatment as usual						Overall	Participant	Trial treatment						Overall
	Massage		Elevation		Compression				Massage		Elevation		Elasticated tape		
1	77.8%	7/9	88.9%	8/9	100%	9/9	**88.8%**	**1***	50%	6/12	50%	6/12	100%	12/12	**66.6%**
							24/27								**24/36**
2	100%	4/4	100%	4/4	100%	4/4	**100%**	**2***	25%	3/12	100%	12/12	16.6%	2/12	**47.2%**
							12/12								**17/36**
3	66.6%	8/12	41.6%	5/12	100%	12/12	**69.4%**	**3**	100%	5/5	0%	0/5	60%	3/5	**53.3%**
							25/36								**8/15**
4	91.6%	11/12	0%	0/12	58.3%	7/12	**50%**	**4**	16.7%	1/6	33.3%	2/6	66.7%	4/6	**38.8%**
							18/36								**7/18**
5	100%	12/12	16.6%	2/12	66.6%	8/12	**61.1%**	**5**	41.6%	5/12	83.3%	10/12	91.6%	11/12	**72.2%**
							22/36								**26/36**
6	100%	9/9	100%	9/9	77.8%	7/9	**92.6%**	**6**	55.6%	5/9	55.6%	5/9	44.4%	4/9	**51.9%**
							25/27								**14/27**
7	Did not return diary							**7**	Not completed		Not completed		66.7%	6/9	**66.7%**
															6/9
Mean	**89.3%**		**57.9%**		**83.8%**			**Mean**	**48.2%**		**53.7%**		**63.7%**		
95% CI	**74.2-100**		**10.4-100**		**63.7-100**			**95% CI**	**16.7-79.7**		**15.6-91.8**		**37.5-89.9**		

Cumulative adherence as a proportion (weeks) and percentages based on the frequency and duration as advised, summarised as a mean adherence for each treatment modality and associated 95% confidence interval for actual treatment time, where known (n=7) **indicates participants who switched treatment from the tape to the glove.*

Outcomes at baseline, 4 and 12 weeks – Mean (Standard Deviation).

	TAU Baseline mean (SD)	TAU 4-week mean (SD)	TAU 12-week mean	TAU mean change baselin-12 weeks (SD)	TT Baseline mean (SD)	TT 4-week mean (SD)	TT 12-week mean (SD)	TT Mean change baseline-12 weeks (SD)
Volumeter (ml)	507.86 (70.23)	490.71 (59.47)	473.57 (60.60)	34.29 (27.75)	505.00 (102.27)	476.43 (103.27)	460.00 (97.47)	45.00 (48.22)
PEM (0-100)	54.17 (16.98)	46.20 (19.39)	38.60 (18.15)	15.57 (18.18)	62.70 (15.61)	44.90 (14.57)	36.31 (16.98)	26.39 (16.40)
ORS (0-6)	3.14 (0.69)	2.43 (0.79)	1.57 (0.79)	1.57 (0.98)	3.57 (0.79)	2.57 (1.13)	2.14 (1.07)	1.43 (1.13)
EQ-5D-5L Utility* (-0.594-1)	0.55 (0.22)	0.65 (0.14)	0.69 (0.21)	0.15 (0.26)	0.64 (0.13)	0.76 (0.13)	0.79 (0.13)	0.16 (0.16)
EQ-5D-5L VAS (0-100)**	68.57 (11.80)	70.71 (14.84)	76.43 (15.74)	7.86 (20.18)	68.57 (11.07)	85.00 (12.91)	85.86 (16.30)	17.29 (21.00)

*a higher score (closer to 1) indicates higher quality of life derived health utility

**a higher score indicates better health states

Legend: TAU= treatment as usual, TT= trial treatment, SD= standard deviation, PEM= patient evaluation measure, ORS= oedema rating scale, VAS=visual analogue scale.

Intention to treat analysis for primary and secondary outcomes at 4 weeks.

	Treatment as usual n=7 Mean (SD)	Trial treatment n=7 Mean (SD)	Adjusted mean difference at 4-weeks unless stated (95% CI)	Linear regression P value
Volumeter (ml)	490.71	476.43	11.99	0.651
	(59.47)	(103.27)	(-44.74 to 68.72)	
PEM (0-100)	46.20	44.90	8.86	0.126
	(19.39)	(14.57)	(-2.92 to 20.64)	
ORS (0-6)				
0-2	3 (43%)	2 (29%)	1.60*	0.692**
3-6	4 (57%)	5 (71%)	(0.16 to 16.23)	
EQ-5D-5L Utility (-0.594- 1)	0.65	0.76	-0.87	0.251
	(0.14)	(0.13)	(-0.25 to 0.07)	
EQ-5D- 5L VAS (0-100)	70.71	85.00	-14.29	0.093
	(14.84)	(12.91)	(-31.36 to 2.79)	

*adjusted (ORS score dichotomized) odds ratio

**logistic regression

Legend: SD= standard deviation, PEM= patient evaluation measure, ORS= oedema rating scale, VAS= visual analogue scale, CI= confidence interval.

Intention to treat analysis for primary and secondary outcomes at 12 weeks.

	Treatment as usual n=7 Mean (SD)	Trial treatment n=7 Mean (SD)	Adjusted mean difference at 12-weeks unless stated (95% CI)	Linear regression P value
Volumeter (ml)	473.57	460.00	11.21	0.591
	(60.60)	(97.47)	(-33.42 to 55.83)	
PEM (0-100)	38.60	36.31	6.70	0.470
	(18.15)	(16.98)	(-12.99 to 26.38)	
ORS (0-6)				
0-2	6 (86%)	4 (57%)	4.29*	0.288**
3-6	1 (14%)	3 (43%)	(0.79 to 63.2)	
EQ-5D-5L Utility (-0.594- 1)	0.69	0.79	-0.081	0.422
	(0.21)	(0.13)	(-0.30 to 0.13)	
EQ-5D- 5L VAS (0-100)	76.43	85.86	-9.43	0.312
	(15.74)	(16.30)	(-29.02 to 10.16)	

*adjusted (ORS score dichotomized) odds ratio

**logistic regression

Legend: SD= standard deviation, PEM= patient evaluation measure, ORS= oedema rating scale, VAS= visual analogue scale, CI= confidence interval.

Adverse events

Trial treatment group (TT)	Treatment as usual group (TAU)
2 participants reported a rash with small bumps under the skin which were sore to touch, or that the tape pulled their skin which resulted in these participants switching to the TAU group.	1 participant reported bruising to the hand which he stated to be as a result of using the compression glove for 24 hours. Following re-assessment by a hand therapist he continued with treatment as usual, although it was not used 'as advised' for the first 6 days because of this.
1 participant reported an itchy rash at her elbow crease where the tape starts, she took a 24-hour rest period from the tape as is advised and continued without any further issues.	